newsfilter
← Latest News
GlobeNewswire·

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling